Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
J Gen Intern Med. 2008 Aug;23(8):1182-6. doi: 10.1007/s11606-008-0636-7. Epub 2008 May 1.
BACKGROUND: Muscle effects are the most common reported adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins). However, in placebo-controlled trials the incidence of muscle pain is most often similar for placebo and active control groups. OBJECTIVE: We sought to evaluate whether statin use was associated with a higher prevalence of musculoskeletal pain in a nationally representative sample. METHODS: Cross-sectional analysis using data from the National Health and Nutrition Examination Survey (NHANES) 1999-2002. Participants were 3,580 adults > or =40 years without arthritis who were interviewed at home and examined in a mobile examination center. Participants were asked about sociodemographic characteristics, health conditions, medication use, and musculoskeletal pain. Height, weight, blood pressure, ankle brachial index, and cholesterol were measured. MEASUREMENTS AND MAIN RESULTS: Prevalence and adjusted odds ratios (OR) of any musculoskeletal pain and musculoskeletal pain in 4 different anatomical regions (neck/upper back, upper extremities, lower back, and lower extremities) by statin use during the last 30 days. Among statin users (n = 402), 22.0% (95%CI 18.0-26.7%) reported musculoskeletal pain in at least 1 anatomical region during the last 30 days, compared with 16.7% (95%CI 15.1-18.4%) of those who did not use a statin. Compared to persons who did not use statins, those who used statins had multivariable-adjusted odds ratios (95%CI; p value) of 1.50 (1.07-2.11; p = .01) for any musculoskeletal pain, 1.59 (1.04-2.44, p = .03) for lower back pain, and 1.50 (1.02-2.22, p = .03) for lower extremity pain. CONCLUSION: Musculoskeletal pain is common in adults > or =40 years without arthritis. In this nationally representative sample, statin users were significantly more likely to report musculoskeletal pain.
背景:肌肉效应是 3-羟基-3-甲基戊二酰辅酶 A 抑制剂(他汀类药物)最常见的不良反应。然而,在安慰剂对照试验中,肌肉疼痛的发生率在安慰剂和活性对照组之间通常相似。
目的:我们旨在评估在具有代表性的全国性样本中,他汀类药物的使用是否与更高的肌肉骨骼疼痛患病率相关。
方法:使用 1999-2002 年全国健康和营养调查(NHANES)的数据进行横断面分析。参与者为 3580 名年龄≥40 岁、无关节炎的成年人,他们在家中接受访谈,并在移动体检中心接受检查。参与者被问及社会人口统计学特征、健康状况、药物使用情况和肌肉骨骼疼痛情况。测量身高、体重、血压、踝肱指数和胆固醇。
测量和主要结果:按他汀类药物使用情况(过去 30 天内)评估任何肌肉骨骼疼痛和 4 个不同解剖区域(颈部/上背部、上肢、下背部和下肢)的肌肉骨骼疼痛的患病率和调整后的比值比(OR)。在他汀类药物使用者(n=402)中,22.0%(95%CI 18.0-26.7%)报告过去 30 天内至少有 1 个解剖区域存在肌肉骨骼疼痛,而未使用他汀类药物者为 16.7%(95%CI 15.1-18.4%)。与未使用他汀类药物者相比,使用他汀类药物者的任何肌肉骨骼疼痛的多变量调整比值比(95%CI;p 值)为 1.50(1.07-2.11;p=0.01),下背部疼痛为 1.59(1.04-2.44,p=0.03),下肢疼痛为 1.50(1.02-2.22,p=0.03)。
结论:肌肉骨骼疼痛在无关节炎的年龄≥40 岁成年人中很常见。在这个具有代表性的全国性样本中,使用他汀类药物者报告肌肉骨骼疼痛的可能性明显更高。